Recent

% | $
Quotes you view appear here for quick access.

BioTime, Inc. Message Board

biopearl 15 posts  |  Last Activity: May 25, 2016 11:20 AM Member since: Jan 27, 2001
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Geron is on the way to $125.00

    by hounddoggiect May 23, 2016 1:21 PM
    biopearl biopearl May 25, 2016 11:20 AM Flag

    Anne, John did not say that Janssen would release interim results. He said if the protocol was modified on the basis of ongoing analysis we would be informed. As far as EU goes, all you can do is hope for a surprise. bp

  • Reply to

    Seems to me

    by rokky44 May 18, 2016 11:22 AM
    biopearl biopearl May 20, 2016 8:58 AM Flag

    rokky44, you are right, he will stand next to the poster as interested attendees approach and discuss the contents with him or his designee, one on one or in small groups. bp

  • Reply to

    Seems to me

    by rokky44 May 18, 2016 11:22 AM
    biopearl biopearl May 19, 2016 6:40 PM Flag

    Rokky44, I think you may have to wait a little longer to hear Dr. T speak since this is a poster not an oral presentation. So unless there is a PR event and Dr.T has something to say there, you will not yet hear his voice. Honestly I am not sure what to think about this poster. I suspect we may get some enrollment data but not much else. The major medical meeting alluded to by Dr. S, I suspect will be ASH. ASH 2017 that is. It seems impossible doesn't it that they wouldn't have CR and PRs to report by now or at least in Dec 2016. There may be something to the obvious unusual nature of presenting heme data at ASCO instead of ASH so there could be something Dr. T wants the heme/onc world to know. My original prediction that the MF study would have to be stopped early for efficacy and for ethical reasons so far has not been borne out. bp

  • biopearl by biopearl May 17, 2016 10:49 AM Flag

    I agree with you. bp

  • biopearl biopearl May 17, 2016 8:57 AM Flag

    Annie hi, that trial completed so I guess there is nothing to take over. I new trial however, building on the info from the Geron study...seems like a strong possibility for Jenssen to me. I am watching the CT site for that. Regards, bp

  • biopearl biopearl May 17, 2016 8:49 AM Flag

    Hello, fata.motgana13. So you belittle senescence? Perhaps you have a little yourself. Just asking. It appears this senesce is good enough to induce fibrotic bone marrow to revert to a normal bone marrow in MF, not good enough? How about abolition of transfusion requirement in MDS? Not good enough? How about a reduction in CSCs in breast cancer and MM. Still not good enough? Some of our best antibiotics are static not cytotoxic. They still save lives. I noticed you were laughing...First seek to understand, then to be understood. Bye, bp

  • Reply to

    $900 Million?

    by blackmarango May 6, 2016 1:06 PM
    biopearl biopearl May 7, 2016 3:47 PM Flag

    Oh come on Cheng. Ho you seem pretty smart and must know the reason there are no insider buys is simple: they can't because of the prior knowledge rule which prevents them from using inside information to influence their decisions bp

  • Reply to

    AACR

    by tazamatic2002 Feb 29, 2016 1:44 PM
    biopearl biopearl Apr 3, 2016 1:11 PM Flag

    Annie I like ptca' style and wish him well. Hope he is not got too much on margin (been there)

  • Reply to

    AACR

    by tazamatic2002 Feb 29, 2016 1:44 PM
    biopearl biopearl Apr 3, 2016 1:07 PM Flag

    Annie not strange at all. AACR is all about basic science, lab and bench work. Geronimo shut that down a while back and understandably would not have too much to say. We will hear from them when clinical trial data reported bp

  • biopearl biopearl Apr 2, 2016 12:33 PM Flag

    odd, This seems like a raw deal to me. The life time of the warrants is measurable in months and the stock price is lower than the warrants and could remain so. Unless Asterias is telegraphing that they expect the stock to go higher because of an "event" it is entirely possible that the warrants will expire worthless or be only minimally higher than the exercise price. Someone explain why this is so wonderful. The closer to Sept the lower the value of the warrants unless the stock goes up. The time frame for exercising should have been longer as an expression of thanks to the shareholders. bp

  • Reply to

    Form 4 Director Filed April 1, 2016

    by anne_hi Apr 1, 2016 11:58 PM
    biopearl biopearl Apr 2, 2016 10:22 AM Flag

    anne hi, thanks for pointing this out. None of the inner circle can buy on the open market since they all have inside info and are unable to act on it overtly by law. When people on this board are screaming about insiders not buying their own stock, that is crazy. They simply can't. So they need to get shares legally--options, stock bonus and fees. bp

  • Reply to

    Stop using PCYC Imbruvica example

    by asherdad13 Apr 1, 2016 10:15 AM
    biopearl biopearl Apr 1, 2016 10:21 AM Flag

    Holly Molly, and intelligent and well written and thoughtful post!! You won't last long here. Please consider joining the YMB refugees on Fishermangent's board: imetelstat.eu

  • Reply to

    Phil's comments on AACR $ misc

    by mangymutt Mar 17, 2016 12:25 AM
    biopearl biopearl Mar 19, 2016 12:40 PM Flag

    Hi Beav, I took you off ignore just to see what your reply to my March 17th post was. I see it was just as irrelevant as your other beaver detritus. I never said AACR was the big reveal and you know it. I do think that if memory serves G has not presented much if anything before at this forum (the AACR conference is more basic science than clinical in nature). I am impressed with the presentations as I have said before and for the reasons mangy has outlined more eloquently than I (go mangy!). Progress is being made and AML Rx more promising by the minute (ok its a very long minute). So beav, back on ignore you go along with many many others. Don't get your tail in a twist! bye bp

  • Reply to

    Phil's comments on AACR $ misc

    by mangymutt Mar 17, 2016 12:25 AM
    biopearl biopearl Mar 17, 2016 9:11 AM Flag

    Well said mangy. 1%!! Thats is fabulous. let me re phrase: 1% after four week so of therapy (albeit in a specific cell line). What then!! What does week five or fifteen look like? Hmmm no data shared bout that. The same with Dr. Lane's mice, how long did they live?? What does relapse look like? Suspect we will have to wait for clinical studies now but the path looks pretty clear and it will be about combos and dosing. They could have data for ASH with this kind of rapid response once the trial is up and running--it should fill fast. We should watch Clin Trials site closely. Very amazing and exciting. 1% viable cell after four weeks. Are you aware of any other benchmark studies for comparison? Thanks for sharing your thoughts. Regards, bp

  • Reply to

    Remission holding strong

    by ryanvball1 Mar 13, 2016 8:34 PM
    biopearl biopearl Mar 14, 2016 8:40 AM Flag

    Ryanvball1, thank you for keeping us posted, your info is greatly appreciated. Ignore the naysayers. bp

BTX
2.88+0.110(+3.97%)May 27 4:00 PMEDT